JP2019052163A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019052163A5 JP2019052163A5 JP2018221977A JP2018221977A JP2019052163A5 JP 2019052163 A5 JP2019052163 A5 JP 2019052163A5 JP 2018221977 A JP2018221977 A JP 2018221977A JP 2018221977 A JP2018221977 A JP 2018221977A JP 2019052163 A5 JP2019052163 A5 JP 2019052163A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- effective amount
- therapeutically effective
- composition according
- receptor agonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 229940098778 Dopamine receptor agonist Drugs 0.000 claims 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 4
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 4
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 2
- 229960003638 dopamine Drugs 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 239000002243 precursor Substances 0.000 claims 2
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- JZKXXXDKRQWDET-QMMMGPOBSA-N L-m-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC(O)=C1 JZKXXXDKRQWDET-QMMMGPOBSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- XNBRWUQWSKXMPW-UHFFFAOYSA-N Tozadenant Chemical compound C1=2SC(NC(=O)N3CCC(C)(O)CC3)=NC=2C(OC)=CC=C1N1CCOCC1 XNBRWUQWSKXMPW-UHFFFAOYSA-N 0.000 claims 1
- 229960004046 apomorphine Drugs 0.000 claims 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 claims 1
- 229960002802 bromocriptine Drugs 0.000 claims 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 claims 1
- 229960004596 cabergoline Drugs 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- NULMGOSOSZBEQL-QMMMGPOBSA-N etilevodopa Chemical compound CCOC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 NULMGOSOSZBEQL-QMMMGPOBSA-N 0.000 claims 1
- 229960001820 etilevodopa Drugs 0.000 claims 1
- 229960001794 melevodopa Drugs 0.000 claims 1
- XBBDACCLCFWBSI-ZETCQYMHSA-N melevodopa Chemical compound COC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 XBBDACCLCFWBSI-ZETCQYMHSA-N 0.000 claims 1
- 229960003089 pramipexole Drugs 0.000 claims 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 claims 1
- 229960001879 ropinirole Drugs 0.000 claims 1
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 claims 1
- 229960003179 rotigotine Drugs 0.000 claims 1
- KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| USPCT/US2010/055681 | 2010-11-05 | ||
| PCT/US2010/055681 WO2012060844A1 (en) | 2010-11-05 | 2010-11-05 | A2a antagonists as cognition and motor function enhancers |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016164379A Division JP6444951B2 (ja) | 2010-11-05 | 2016-08-25 | 認知機能および運動機能の増強剤としてのａ２ａアンタゴニスト |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019052163A JP2019052163A (ja) | 2019-04-04 |
| JP2019052163A5 true JP2019052163A5 (enExample) | 2019-05-16 |
| JP6611896B2 JP6611896B2 (ja) | 2019-11-27 |
Family
ID=46024745
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013537896A Expired - Fee Related JP6315991B2 (ja) | 2010-11-05 | 2011-11-04 | 認知機能および運動機能の増強剤としてのａ２ａアンタゴニスト |
| JP2016164379A Expired - Fee Related JP6444951B2 (ja) | 2010-11-05 | 2016-08-25 | 認知機能および運動機能の増強剤としてのａ２ａアンタゴニスト |
| JP2018221977A Expired - Fee Related JP6611896B2 (ja) | 2010-11-05 | 2018-11-28 | 認知機能および運動機能の増強剤としてのａ２ａアンタゴニスト |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013537896A Expired - Fee Related JP6315991B2 (ja) | 2010-11-05 | 2011-11-04 | 認知機能および運動機能の増強剤としてのａ２ａアンタゴニスト |
| JP2016164379A Expired - Fee Related JP6444951B2 (ja) | 2010-11-05 | 2016-08-25 | 認知機能および運動機能の増強剤としてのａ２ａアンタゴニスト |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20130317019A1 (enExample) |
| EP (1) | EP2635256B1 (enExample) |
| JP (3) | JP6315991B2 (enExample) |
| KR (2) | KR102166229B1 (enExample) |
| CN (3) | CN107281491A (enExample) |
| AU (3) | AU2011323152A1 (enExample) |
| BR (1) | BR112013011068A2 (enExample) |
| CA (1) | CA2816834A1 (enExample) |
| EA (2) | EA202091356A1 (enExample) |
| ES (1) | ES2842968T3 (enExample) |
| HK (1) | HK1245138A1 (enExample) |
| IL (2) | IL225868B (enExample) |
| MX (2) | MX382823B (enExample) |
| NZ (2) | NZ609803A (enExample) |
| WO (2) | WO2012060844A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6339758B2 (ja) * | 2012-07-02 | 2018-06-06 | 国立研究開発法人国立長寿医療研究センター | 軽度認知機能障害の有無の診断システム、認知機能検査用端末及び認知機能検査用プログラム |
| JO3544B1 (ar) * | 2015-03-19 | 2020-07-05 | Kyowa Kirin Co Ltd | عامل علاجي للاختلال الوظيفي في الفص الجبهي |
| AU2016278846B2 (en) | 2015-06-19 | 2021-08-05 | Biotie Therapies, Inc. | Controlled-release tozadenant formulations |
| EP4501406A3 (en) * | 2016-04-19 | 2025-03-26 | IntraBio Ltd | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function |
| US11246871B2 (en) | 2016-07-15 | 2022-02-15 | Northwestern University | Targeting adenosine A2A receptors for the treatment of levodopa-induced dyskinesias |
| WO2018059531A1 (zh) * | 2016-09-30 | 2018-04-05 | 苏州晶云药物科技有限公司 | 一种腺苷a2a受体拮抗剂药物的晶型及其制备方法和用途 |
| CA3126735A1 (en) | 2019-01-11 | 2020-07-16 | Omeros Corporation | Methods and compositions for treating cancer |
| CN115397425A (zh) * | 2019-12-02 | 2022-11-25 | 希诺皮亚生物科学公司 | 使用曲匹地尔治疗认知障碍 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040198753A1 (en) * | 2002-01-28 | 2004-10-07 | Hiroshi Kase | Methods of treating patients suffering from movement disorders |
| EP1753760B1 (en) * | 2004-05-24 | 2008-01-02 | F.Hoffmann-La Roche Ag | 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide |
| US7576073B2 (en) * | 2004-05-28 | 2009-08-18 | UNIVERSITé LAVAL | Combined therapy for the treatment of parkinson's disease |
| US8168785B2 (en) * | 2009-06-17 | 2012-05-01 | Biotie Therapies, Inc. | Benzothiazole derivatives |
-
2010
- 2010-11-05 WO PCT/US2010/055681 patent/WO2012060844A1/en not_active Ceased
-
2011
- 2011-11-04 US US13/882,132 patent/US20130317019A1/en not_active Abandoned
- 2011-11-04 WO PCT/US2011/059466 patent/WO2012061787A1/en not_active Ceased
- 2011-11-04 NZ NZ609803A patent/NZ609803A/en not_active IP Right Cessation
- 2011-11-04 EA EA202091356A patent/EA202091356A1/ru unknown
- 2011-11-04 KR KR1020197005483A patent/KR102166229B1/ko not_active Expired - Fee Related
- 2011-11-04 EP EP11838922.0A patent/EP2635256B1/en active Active
- 2011-11-04 NZ NZ746118A patent/NZ746118A/en not_active IP Right Cessation
- 2011-11-04 AU AU2011323152A patent/AU2011323152A1/en not_active Abandoned
- 2011-11-04 MX MX2017009051A patent/MX382823B/es unknown
- 2011-11-04 CN CN201710583855.5A patent/CN107281491A/zh active Pending
- 2011-11-04 ES ES11838922T patent/ES2842968T3/es active Active
- 2011-11-04 KR KR1020137014385A patent/KR101955045B1/ko not_active Expired - Fee Related
- 2011-11-04 CN CN201811049033.XA patent/CN109223799A/zh active Pending
- 2011-11-04 EA EA201390653A patent/EA035900B1/ru not_active IP Right Cessation
- 2011-11-04 BR BR112013011068A patent/BR112013011068A2/pt not_active IP Right Cessation
- 2011-11-04 MX MX2013005014A patent/MX2013005014A/es unknown
- 2011-11-04 CA CA2816834A patent/CA2816834A1/en not_active Abandoned
- 2011-11-04 JP JP2013537896A patent/JP6315991B2/ja not_active Expired - Fee Related
- 2011-11-04 CN CN2011800534450A patent/CN103429221A/zh active Pending
-
2013
- 2013-04-21 IL IL225868A patent/IL225868B/en active IP Right Grant
-
2016
- 2016-08-25 JP JP2016164379A patent/JP6444951B2/ja not_active Expired - Fee Related
-
2017
- 2017-03-02 AU AU2017201446A patent/AU2017201446A1/en not_active Abandoned
-
2018
- 2018-04-13 HK HK18104835.1A patent/HK1245138A1/zh unknown
- 2018-11-28 JP JP2018221977A patent/JP6611896B2/ja not_active Expired - Fee Related
- 2018-12-28 AU AU2018286608A patent/AU2018286608B2/en not_active Ceased
-
2019
- 2019-04-29 IL IL266321A patent/IL266321A/en unknown
-
2021
- 2021-06-07 US US17/341,106 patent/US20220125772A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019052163A5 (enExample) | ||
| JP2011522816A5 (enExample) | ||
| JP2019524822A5 (enExample) | ||
| JP2014511374A5 (enExample) | ||
| JP2017075173A5 (enExample) | ||
| JP2007145875A5 (enExample) | ||
| JP2012523430A5 (enExample) | ||
| JP2009534312A5 (enExample) | ||
| JP2013526609A5 (enExample) | ||
| RU2015117267A (ru) | Замещенные соединения амида | |
| JP2014062126A5 (enExample) | ||
| RU2018103338A (ru) | Производные диарил- и арилгетероарилмочевины для профилактики и лечения галлюцинаций, ассоциированных с нейродегенеративным заболеванием | |
| JP2018516992A5 (enExample) | ||
| EP2323641A4 (en) | NYASOL AND ANALOGUE THEREOF FOR THE TREATMENT OF ESTROGEN RECEPTOR-BETA-MEDIATED ILLNESSES | |
| CL2017001853A1 (es) | Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma (divisional de solicitud n°1707-2016). | |
| JP2013502446A5 (enExample) | ||
| CN101678005A (zh) | 毒蕈碱性受体拮抗剂和β-2肾上腺素受体激动剂的组合 | |
| EA201071006A1 (ru) | Набор, композиция, продукт или лекарственное средство для лечения нарушения познавательной способности | |
| BRPI0517227A (pt) | forma de dosagem oral de liberação prolongada do ácido 1-{[alfa-isobutanoiloxietoxi)carbonil]amino metil}-1-cicloexano acético, e, método de tratamento de uma doença ou condição | |
| JP2014050390A5 (enExample) | ||
| FI3886917T3 (fi) | Kuparinanoklusterit, niitä sisältävät koostumukset ja neurodegeneratiivisten sairauksien hoito | |
| EA201390653A1 (ru) | Aa антагонисты как усилители когнитивной и моторной функций | |
| MX2011011490A (es) | Derivados de isoxazol-tiazol como agonistas inversos del receptor de acido gamma-aminobutirico a (gaba a), para usarse en el tratamiento de trastornos cognitivos. | |
| JP2017503756A5 (enExample) | ||
| JP2008515980A5 (enExample) |